NO20003108L - Use of melatonin energetic ligands in the preparation of pharmaceutical compositions - Google Patents

Use of melatonin energetic ligands in the preparation of pharmaceutical compositions

Info

Publication number
NO20003108L
NO20003108L NO20003108A NO20003108A NO20003108L NO 20003108 L NO20003108 L NO 20003108L NO 20003108 A NO20003108 A NO 20003108A NO 20003108 A NO20003108 A NO 20003108A NO 20003108 L NO20003108 L NO 20003108L
Authority
NO
Norway
Prior art keywords
melatonin
pharmaceutical compositions
preparation
energetic
ligands
Prior art date
Application number
NO20003108A
Other languages
Norwegian (no)
Other versions
NO20003108D0 (en
Inventor
Sonia Pellissier
Anne Merle
Philippe Delagrange
Caroline Bennejean
Pierre Renard
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of NO20003108D0 publication Critical patent/NO20003108D0/en
Publication of NO20003108L publication Critical patent/NO20003108L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anvendelse av melatonin og melatoninergiske Ugander for å oppnå farmasøytiske sammensetninger for forebyggingen ¿ og/eller behandlingen av patologier i det gastrointestinale system.Use of melatonin and melatoninergic Ugands to obtain pharmaceutical compositions for the prevention ¿and / or treatment of pathologies in the gastrointestinal system.

NO20003108A 1999-06-23 2000-06-16 Use of melatonin energetic ligands in the preparation of pharmaceutical compositions NO20003108L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9908019A FR2795323B1 (en) 1999-06-23 1999-06-23 USE OF MELATONINERGIC LIGANDS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE GASTROINTESTINAL SYSTEM

Publications (2)

Publication Number Publication Date
NO20003108D0 NO20003108D0 (en) 2000-06-16
NO20003108L true NO20003108L (en) 2000-12-27

Family

ID=9547206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003108A NO20003108L (en) 1999-06-23 2000-06-16 Use of melatonin energetic ligands in the preparation of pharmaceutical compositions

Country Status (15)

Country Link
EP (1) EP1064941A1 (en)
JP (1) JP2001026539A (en)
KR (1) KR20010039680A (en)
CN (1) CN1283455A (en)
AU (1) AU4264800A (en)
BR (1) BR0002772A (en)
CA (1) CA2312432A1 (en)
EA (1) EA002823B1 (en)
FR (1) FR2795323B1 (en)
HU (1) HUP0002377A3 (en)
MX (1) MXPA00006145A (en)
NO (1) NO20003108L (en)
NZ (1) NZ505361A (en)
PL (1) PL340954A1 (en)
ZA (1) ZA200003165B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249785A1 (en) * 2003-08-13 2005-11-10 Gordon John G Use of melatonin-containing oral supplement with animals
US9408405B2 (en) 2003-10-03 2016-08-09 Veijlen N.V. Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
CN1870992A (en) 2003-10-03 2006-11-29 维伊林股份有限公司 Animal feed composition
RU2361583C2 (en) * 2003-10-03 2009-07-20 Вейлен Н.В. Application of compositions, capable to raise level of igf-1 in blood serum, at preparation of therapeutic composition for treatment of stages of various diseases, associated with depression of igf-1 level in serum of people and animals
CA2644181A1 (en) * 2006-03-20 2007-09-27 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for irritable bowel syndrome
ES2384798B1 (en) * 2011-10-19 2013-06-04 Universidad De Granada USE OF MELATONIN FOR THE TREATMENT AND / OR PREVENTION OF MUCOSITIS.
RU2693044C1 (en) * 2018-05-28 2019-07-01 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет) ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеч Method for prevention of nsaid-gastropathy
WO2022157563A1 (en) * 2021-01-23 2022-07-28 Cellix Bio Private Limited A pharmaceutical composition comprising lidocaine and melatonin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729147A1 (en) * 1995-01-11 1996-07-12 Adir NOVEL ALKYL CYCLIC (HETERO) COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
NO20003108D0 (en) 2000-06-16
HUP0002377A3 (en) 2002-08-28
CN1283455A (en) 2001-02-14
EA200000568A2 (en) 2000-12-25
CA2312432A1 (en) 2000-12-23
PL340954A1 (en) 2001-01-02
EA200000568A3 (en) 2001-02-26
BR0002772A (en) 2001-01-30
AU4264800A (en) 2001-01-04
HUP0002377A2 (en) 2002-05-29
KR20010039680A (en) 2001-05-15
FR2795323B1 (en) 2001-11-16
JP2001026539A (en) 2001-01-30
EA002823B1 (en) 2002-10-31
EP1064941A1 (en) 2001-01-03
FR2795323A1 (en) 2000-12-29
ZA200003165B (en) 2001-01-25
MXPA00006145A (en) 2002-10-17
NZ505361A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
YU46097A (en) Novel class of esters and their pharmaceutical compositions
ATE265857T1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE PREVENTION OR TREATMENT OF HYPEROXALUria
ATE429210T1 (en) ORAL LIQUID COMPOSITIONS
DE10082139T1 (en) Composition for the treatment of friction pairs
HRP920632B1 (en) Oral composition for the treatment of inflammatory bowel deseases
TNSN99171A1 (en) 4-CARBOXYAMINO-2-SUBSTITUE-1,2,3,4-TETRAHYDROQUINOLEINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE455106T1 (en) ACYL DERIVATIVES FOR THE TREATMENT OF VLA-4 RELATED DISEASES
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
DE60032795D1 (en) NORDIHYDROGUAIARETINIC ACID DERIVATIVES FOR THE TREATMENT OF TUMORS
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
CA2408537A1 (en) Treating irritable bowel syndrome or disease
ATE295174T1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF HYPERTENSION
DK0946157T3 (en) Topical use of kappa-opioid agonists for the treatment of eye pain
ATE325803T1 (en) GLYCOCONJUGATES, GLYCOAMINO ACIDS, THEIR INTERMEDIATE PRODUCTS, AND THEIR USE
NO993784D0 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
ATE296635T1 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO CELLULAR DISEASES OF THE EYE BACKGROUND
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
EA200000568A2 (en) Use of melatonin and melatoninergic ligands in obtaining pharmaceutical compositions intended for prevention or treatment of pathologies of the gastrointestinal system
EP1161255A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
GB0016052D0 (en) Ruthenium (II) compounds
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application